Literature DB >> 21627335

Administration of CREON® pancrelipase pellets via gastrostomy tube is feasible with no loss of gastric resistance or lipase activity: an in vitro study.

George Shlieout1, Andreas Koerner, Mario Maffert, Kristin Forssmann, Steven Caras.   

Abstract

BACKGROUND AND OBJECTIVES: In clinical practice, the need sometimes arises to administer pancreatic enzyme replacement therapy via gastrostomy tube (G-tube) by mixing the pellets contained in the capsules with soft food. The objective of this study was to identify G-tubes that allow administration of pancrelipase gastro-resistant pellets without clogging, sticking, pellet damage or loss of enteric coating integrity.
METHODS: In this in vitro study, CREON® (pancrelipase) Delayed-Release Capsules were opened and the pellets sprinkled onto a small amount of baby food of pH <4.5 (applesauce and bananas manufactured by both Gerber and Beech-Nut). The mixture was stirred gently and after 15 minutes poured into a 35 mL syringe and pushed slowly (~15 mL in 10-15 seconds) through a G-tube. Pellets were collected and the tube flushed with water. G-tubes were inspected visually for clogging/sticking and damage to pellets was assessed. If there was none with all four foods, pellet integrity (gastric resistance and lipase activity) was assessed by an in vitro dissolution method with a 2-hour gastric simulation step. The activity required to confirm integrity was ≥80% of actual US Pharmacopeia lipase activity per capsule. G-tubes initially tested were Kimberly-Clark MIC Bolus® size 14 French (Fr) and upwards and Kimberly-Clark MIC-KEY® 14 Fr and upwards. Following successful testing, assessment of Bard® Tri-Funnel 18 Fr and Bard® Button 18 Fr G-tubes was carried out.
RESULTS: Based on the absence of clogging, sticking and visible damage to pellets, and the maintenance of pellet integrity, administration of CREON® pancrelipase pellets was feasible through the following G-tubes: Kimberly-Clark MIC Bolus® size 18 Fr, Kimberly-Clark MIC-KEY® 16 Fr, Bard® Tri-Funnel 18 Fr and Bard® Button 18 Fr. Lipase activity met the predetermined specification and was ≥90% for all four tubes and all four foods, with no differences versus untreated pellets (i.e. pellets not mixed with baby food or pushed through a G-tube). These data apply to all CREON® pancrelipase capsule formulations, regardless of their strength in lipase units, as pellet composition, size and quality are identical.
CONCLUSION: CREON® pancrelipase pellets can be mixed with baby food of pH <4.5 and administered via the following G-tubes without clogging, sticking or visible pellet damage, and with no loss of gastric resistance or lipase activity: Kimberly-Clark MIC Bolus® size 18 Fr and larger, Kimberly-Clark MIC-KEY® 16 Fr and larger, Bard® Tri-Funnel 18 Fr and larger and Bard® Button 18 Fr and larger.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21627335     DOI: 10.2165/11592990-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  18 in total

Review 1.  Nutrition in patients with cystic fibrosis: a European Consensus.

Authors:  M Sinaasappel; M Stern; J Littlewood; S Wolfe; G Steinkamp; Harry G M Heijerman; E Robberecht; G Döring
Journal:  J Cyst Fibros       Date:  2002-06       Impact factor: 5.482

2.  Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.

Authors:  Gavin R Graff; Karen Maguiness; John McNamara; Ronald Morton; David Boyd; Katrin Beckmann; Djenane Bennett
Journal:  Clin Ther       Date:  2010-01       Impact factor: 3.393

3.  Stature as a prognostic factor in cystic fibrosis survival.

Authors:  L T Beker; E Russek-Cohen; R J Fink
Journal:  J Am Diet Assoc       Date:  2001-04

4.  A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.

Authors:  R C Stern; J D Eisenberg; J S Wagener; R Ahrens; M Rock; G doPico; D M Orenstein
Journal:  Am J Gastroenterol       Date:  2000-08       Impact factor: 10.864

5.  Percutaneous endoscopic gastrostomy in cystic fibrosis: patient acceptance and effect of overnight tube feeding on nutritional status.

Authors:  S Van Biervliet; K De Waele; M Van Winckel; E Robberecht
Journal:  Acta Gastroenterol Belg       Date:  2004 Jul-Sep       Impact factor: 1.316

6.  The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis.

Authors:  Michael Safdi; Pradeep K Bekal; Stephen Martin; Zahid A Saeed; Frank Burton; Phillip P Toskes
Journal:  Pancreas       Date:  2006-08       Impact factor: 3.327

7.  Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis.

Authors:  Michael W Konstan; Steven M Butler; Mary Ellen B Wohl; Marcia Stoddard; Robert Matousek; Jeffrey S Wagener; Charles A Johnson; Wayne J Morgan
Journal:  J Pediatr       Date:  2003-06       Impact factor: 4.406

8.  Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study.

Authors:  Carla Colombo; Clara Fredella; Maria Chiara Russo; Nadia Faelli; Valentina Motta; Lauretta Valmarana; Luigina Longo; Ciro D'Orazio
Journal:  Pancreas       Date:  2009-08       Impact factor: 3.327

9.  Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.

Authors:  Bruce C Trapnell; Karen Maguiness; Gavin R Graff; David Boyd; Katrin Beckmann; Steven Caras
Journal:  J Cyst Fibros       Date:  2009-10-07       Impact factor: 5.482

Review 10.  Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review.

Authors:  Virginia A Stallings; Lori J Stark; Karen A Robinson; Andrew P Feranchak; Hebe Quinton
Journal:  J Am Diet Assoc       Date:  2008-05
View more
  5 in total

Review 1.  Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century.

Authors:  Tony Trang; Johanna Chan; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

2.  Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency.

Authors:  Kei Nakajima; Haruki Oshida; Toshitaka Muneyuki; Masafumi Kakei
Journal:  Core Evid       Date:  2012-07-19

3.  Individualized pharmaceutical care for a patient after pancreaticoduodenectomy with trypsin replacement nutritional therapy: A case report.

Authors:  Song Zhang; Qin Tan; Hanjun He
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

Review 4.  Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines.

Authors:  Mary E Phillips; Andrew D Hopper; John S Leeds; Keith J Roberts; Laura McGeeney; Sinead N Duggan; Rajesh Kumar
Journal:  BMJ Open Gastroenterol       Date:  2021-06

5.  Crushing pancreatic enzymes with enteral feeds in an extremely premature infant with cystic fibrosis-a novel and effective technique.

Authors:  Jodi Grunert; Andrew Tai
Journal:  Eur J Clin Nutr       Date:  2020-08-28       Impact factor: 4.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.